Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

APMIS is a distinguished academic journal published by WILEY that serves as a vital resource for researchers and practitioners in the fields of Immunology, Allergy, Microbiology, and Pathology. Established in 1988 and continuing its mission through 2024, this journal facilitates the dissemination of high-quality research findings, contributing to the intersection of multiple disciplines within the medical sciences. With an ISSN of 0903-4641 and an E-ISSN of 1600-0463, APMIS is categorized in 2023's Q2 and Q3 quartiles across various domains, reflecting its significant impact, with rankings such as #50/208 in Pathology and Forensic Medicine and #121/233 in Immunology and Allergy. Although it currently does not offer open access options, the journal’s rigorous peer-review process ensures that published articles maintain the highest standards of scholarship. With its focus on innovative research, APMIS continues to occupy a pivotal role for those seeking to advance their expertise and contribute to scientific dialogue in these essential fields.

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

CLINICAL IMMUNOLOGY is a premier academic journal dedicated to the field of immunology, published by Academic Press Inc. Elsevier Science. With a robust impact reflected in its recent categorization as Q2 in Immunology and Q1 in Immunology and Allergy for 2023, this journal stands out as a key resource for researchers and professionals alike. Featuring a diverse array of articles from fundamental laboratory studies to advanced clinical applications, CLINICAL IMMUNOLOGY aims to disseminate significant research findings that contribute to the evolving landscape of immunological science. Its notable Scopus rankings underscore its esteemed position, with ranks of #33 and #36 in the respective categories, highlighting its commitment to high-quality scholarly work. Although not an open-access journal, it ensures access to valuable insights and developments in the immune response and related fields, making it an indispensable tool for students and professionals aiming to stay at the forefront of immunological research.

Immunopathologia Persa, published by NIKAN RESEARCH INST, is a premier open-access journal specializing in the fields of immunology, hematology, and endocrinology. Since its inception in 2015, the journal has aimed to disseminate high-quality research and innovative insights critical to understanding immune responses, disease mechanisms, and therapeutic strategies. Based in Iran, the journal contributes significantly to the academic landscape, with quarterly categorizations placing it in the fourth quartile across multiple vital sectors including Endocrinology, Diabetes and Metabolism, and Immunology. It features a diverse range of articles and studies that cater to both emerging and established researchers, aiding in the advancement of knowledge and clinical practice in immunopathology. With its commitment to open access, Immunopathologia Persa ensures that cutting-edge research is readily available to all, fostering a collaborative research environment and promoting the dissemination of findings globally. Researchers, professionals, and students are encouraged to explore the contents of this journal to stay abreast of the latest developments in these critical areas of health science.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

ANNALS OF CLINICAL AND LABORATORY SCIENCE, published by the Association of Clinical Scientists, is a pivotal journal in the fields of clinical biochemistry, hematology, immunology, and medical laboratory technology. Since its inception in 1971, this journal has become a vital resource for researchers and practitioners aiming to advance their knowledge and skills in laboratory sciences. Although currently not an open access journal, its rich repository of peer-reviewed articles and studies contributes significantly to the academic discourse in diagnostic and therapeutic practices. The journal is categorized in various quartiles, reflecting its impact and contributions to multiple scientific domains, such as Q4 in Clinical Biochemistry and Q3 in Pathology and Forensic Medicine as of 2023. With an extensive convergence of years up to 2024, it proves to be a timeless source for emerging trends and research innovations. The ANNALS OF CLINICAL AND LABORATORY SCIENCE not only supports the professional development of its readers but also encourages interdisciplinary collaboration, making it an essential tool for professionals, students, and researchers dedicated to improving health outcomes through advanced laboratory sciences.

HUMAN IMMUNOLOGY, published by Elsevier Science Inc, serves as a critical platform for disseminating research in the fields of immunology and allergy, as well as various aspects of miscellaneous medicine since its inception in 1980. With an ISSN of 0198-8859 and E-ISSN 1879-1166, this journal is pivotal for researchers and practitioners looking to advance their understanding of human immune responses and related conditions. The journal currently holds a respectable position within its field, as highlighted by its 2023 Scopus ranks—#114/233 in Immunology and Allergy and #132/236 in Immunology and Microbiology. Moreover, it maintains a Q2 quartile ranking in both Immunology and Allergy and miscellaneous Medicine, underscoring its influence and reach within the scientific community. Although it does not currently offer Open Access options, HUMAN IMMUNOLOGY remains dedicated to providing valuable insights and fostering academic discourse within its discipline, characterized by a rigorous peer-review process and a focus on innovative research trajectories.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.